On November 19, 2020 OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4), reported that data from the OBI-833 Phase 1 clinical study targeting the Globo H antigen in lung cancer will be presented at the European Society of Clinical Oncology Asia (ESMO Asia) 2020 Virtual Scientific Program from November 20-22, 2020 (Press release, OBI Pharma, NOV 19, 2020, View Source [SID1234571406]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833.
"Based upon our anti-Globo H targeted approaches in cancers of high unmet needs, OBI Pharma is proud to have presentations on the progress of our trial presented at ESMO (Free ESMO Whitepaper)-Asia 2020 for our novel therapeutic cancer vaccine, OBI-833." Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, "In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. In addition, OBI-833 can elicit a beneficial immune response in NSCLC patients and had rendered some TKI-treated patients a durable stable disease status. We look forward to providing updates of our study, which we believe could offer potential therapeutic benefits to patients suffering from lung cancer."
1. Presentation number: 397P / Poster: ID 680
Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients
Presenter: Ching-Liang Ho MD, et.al. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan.
Session Title: E-poster Display session – Thoracic tumours, metastatic
Session Date and Time: Friday, November 20, 2020. 9:00 – 20:00 Eastern Time
2. Presentation number: 71MO / Oral: ID 798
Title: OBI-833 was safe and immunogenic, without treatment-related SAEs, in a Phase 1 dose-escalation trial
Presenter: Her-Shyong Shiah, MD*., et.al. Department of Hematology and Oncology, Taipei Medical University Hospital, Taipei, Taiwan
*current affiliation: Department of Hematology and Oncology, Taipei Tzu Chi Hospital, Taipei, Taiwan
Session Title: Mini-oral session – Developmental and Precision Medicine
Session Date and Time: Friday, November 20, 2020. 19:52 – 19:57 Eastern Time
The above poster presentations will be available online at www.obipharma.com on November 23, 2020